Skip to content

Study · Ex vivo tissue · rabbit · 2018

7 results

Effects of α-Lipoic Acid, Carnosine, and Thiamine Supplementation in Obese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind Study.

Karkabounas S, Papadopoulos N, Anastasiadou C, Gubili C, Peschos D, Daskalou T, Fikioris N, Simos YV, Kontargiris E, Gianakopoulos X, Ragos V, Chatzidimitriou M

Journal of medicinal food11 Oct 2018Cited by 39 (Europe PMC)

PMID30311825 (opens in a new tab)DOI10.1089/jmf.2018.0007 (opens in a new tab)PepBankPUB-30311825
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In human and rabbit platelet tests, carnosine did not inhibit aggregation through the tested pathways, whereas ALA did.

    In plain wordsIn lab tests with human and rabbit platelets, carnosine did not inhibit aggregation through the tested pathways, whereas ALA did.

    Peptide
    L-carnosine
    Outcome
    No significant changePlatelet aggregation across tested pathways
    Study

    human and rabbitn: not reported in source

    Human and washed rabbit platelets
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Only ALA inhibited platelets aggregation ex vivo through ADP, platelet activating factor, arachidonic acid, epinephrine, collagen, and thrombin pathways.
    1 context sentence
    Summary · context
    Moreover, the antiplatelet activity of each of the supplement's components was determined ex vivo at human and washed rabbit platelets.

Studies that did not test the peptide alone6

In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking L-carnosine.

  1. 02HumanNot a test of L-carnosine aloneRandomized controlled trialEfficacy outcome

    In obese patients with diabetes, the ALA/carnosine/thiamine supplement significantly reduced glucose after supplementation.

    In plain wordsIn obese patients with diabetes, the ALA/carnosine/thiamine combination significantly reduced glucose after supplementation.

    Peptide
    L-carnosine
    Outcome
    DecreaseGlucose
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Glucose
    135.7 mg/dL
    before supplementation
    Glucose
    126.5 mg/dL
    after supplementation

    Source sentences

    Summary
    Glucose and HbA1c levels were significantly reduced after supplementation (135.7 ± 19.5 mg/dL vs. 126.5 ± 16.8 mg/dL and 8.3% ± 0.3% vs. 6.03% ± 0.58%, respectively, P < .05); however, insulin was significantly increased (3.6 ± 0.7 μIU/mL vs. 6.8 ± 0.2 μIU/mL, P < .05).
    2 context sentences
    Summary · context
    We performed a randomized double-blind placebo-controlled trial to investigate the effectiveness of an individualized oral supplementation with α-lipoic acid (ALA), carnosine, and thiamine.
    Summary · context
    For that purpose, 82 obese type 2 diabetic patients were randomly assigned to 2 groups, and were either supplemented daily with 7 mg ALA/kg body weight, 6 mg carnosine/kg body weight, and 1 mg thiamine/kg body weight or placebo for 8 weeks.

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  2. 03HumanNot a test of L-carnosine aloneRandomized controlled trialEfficacy outcome

    In obese patients with diabetes, the ALA/carnosine/thiamine supplement significantly reduced HbA1c after supplementation.

    In plain wordsIn obese patients with diabetes, the ALA/carnosine/thiamine combination significantly reduced HbA1c after supplementation.

    Peptide
    L-carnosine
    Outcome
    DecreaseHbA1c
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c
    8.3%
    before supplementation
    HbA1c
    6.03%
    after supplementation

    Source sentences

    Summary
    Glucose and HbA1c levels were significantly reduced after supplementation (135.7 ± 19.5 mg/dL vs. 126.5 ± 16.8 mg/dL and 8.3% ± 0.3% vs. 6.03% ± 0.58%, respectively, P < .05); however, insulin was significantly increased (3.6 ± 0.7 μIU/mL vs. 6.8 ± 0.2 μIU/mL, P < .05).
    2 context sentences
    Summary · context
    We performed a randomized double-blind placebo-controlled trial to investigate the effectiveness of an individualized oral supplementation with α-lipoic acid (ALA), carnosine, and thiamine.
    Summary · context
    For that purpose, 82 obese type 2 diabetic patients were randomly assigned to 2 groups, and were either supplemented daily with 7 mg ALA/kg body weight, 6 mg carnosine/kg body weight, and 1 mg thiamine/kg body weight or placebo for 8 weeks.

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  3. 04HumanNot a test of L-carnosine aloneRandomized controlled trialEfficacy outcome

    In obese patients with diabetes, the ALA/carnosine/thiamine supplement significantly increased insulin after supplementation.

    In plain wordsIn obese patients with diabetes, the ALA/carnosine/thiamine combination significantly increased insulin after supplementation.

    Peptide
    L-carnosine
    Outcome
    IncreaseInsulin
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Insulin
    3.6 μIU/mL
    before supplementation
    Insulin
    6.8 μIU/mL
    after supplementation

    Source sentences

    Summary
    Glucose and HbA1c levels were significantly reduced after supplementation (135.7 ± 19.5 mg/dL vs. 126.5 ± 16.8 mg/dL and 8.3% ± 0.3% vs. 6.03% ± 0.58%, respectively, P < .05); however, insulin was significantly increased (3.6 ± 0.7 μIU/mL vs. 6.8 ± 0.2 μIU/mL, P < .05).
    2 context sentences
    Summary · context
    We performed a randomized double-blind placebo-controlled trial to investigate the effectiveness of an individualized oral supplementation with α-lipoic acid (ALA), carnosine, and thiamine.
    Summary · context
    For that purpose, 82 obese type 2 diabetic patients were randomly assigned to 2 groups, and were either supplemented daily with 7 mg ALA/kg body weight, 6 mg carnosine/kg body weight, and 1 mg thiamine/kg body weight or placebo for 8 weeks.

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  4. 05HumanNot a test of L-carnosine aloneRandomized controlled trialEfficacy outcome

    In obese patients with diabetes, the ALA/carnosine/thiamine supplement produced higher follow-up HOMA-IR values.

    In plain wordsIn obese patients with diabetes, the ALA/carnosine/thiamine combination produced higher follow-up HOMA-IR values.

    Peptide
    L-carnosine
    Outcome
    IncreaseHOMA-IR
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The patients treated with the supplement recorded higher follow-up values for HOMA-IR and HOMA-β, and a significant drop in serum hydroperoxide level.
    2 context sentences
    Summary · context
    We performed a randomized double-blind placebo-controlled trial to investigate the effectiveness of an individualized oral supplementation with α-lipoic acid (ALA), carnosine, and thiamine.
    Summary · context
    For that purpose, 82 obese type 2 diabetic patients were randomly assigned to 2 groups, and were either supplemented daily with 7 mg ALA/kg body weight, 6 mg carnosine/kg body weight, and 1 mg thiamine/kg body weight or placebo for 8 weeks.

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  5. 06HumanNot a test of L-carnosine aloneRandomized controlled trialEfficacy outcome

    In obese patients with diabetes, the ALA/carnosine/thiamine supplement produced higher follow-up HOMA-beta values.

    In plain wordsIn obese patients with diabetes, the ALA/carnosine/thiamine combination produced higher follow-up HOMA-beta values.

    Peptide
    L-carnosine
    Outcome
    IncreaseHOMA-beta
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The patients treated with the supplement recorded higher follow-up values for HOMA-IR and HOMA-β, and a significant drop in serum hydroperoxide level.
    2 context sentences
    Summary · context
    We performed a randomized double-blind placebo-controlled trial to investigate the effectiveness of an individualized oral supplementation with α-lipoic acid (ALA), carnosine, and thiamine.
    Summary · context
    For that purpose, 82 obese type 2 diabetic patients were randomly assigned to 2 groups, and were either supplemented daily with 7 mg ALA/kg body weight, 6 mg carnosine/kg body weight, and 1 mg thiamine/kg body weight or placebo for 8 weeks.

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  6. 07HumanNot a test of L-carnosine aloneRandomized controlled trialEfficacy outcome

    In obese patients with diabetes, the ALA/carnosine/thiamine supplement significantly reduced serum hydroperoxide.

    In plain wordsIn obese patients with diabetes, the ALA/carnosine/thiamine combination significantly reduced serum hydroperoxide.

    Peptide
    L-carnosine
    Outcome
    DecreaseSerum hydroperoxide
    Study

    n: not reported in source

    Outcome group
    Oxidative stress · Metabolic and weight

    Source sentences

    Summary
    The patients treated with the supplement recorded higher follow-up values for HOMA-IR and HOMA-β, and a significant drop in serum hydroperoxide level.
    2 context sentences
    Summary · context
    We performed a randomized double-blind placebo-controlled trial to investigate the effectiveness of an individualized oral supplementation with α-lipoic acid (ALA), carnosine, and thiamine.
    Summary · context
    For that purpose, 82 obese type 2 diabetic patients were randomly assigned to 2 groups, and were either supplemented daily with 7 mg ALA/kg body weight, 6 mg carnosine/kg body weight, and 1 mg thiamine/kg body weight or placebo for 8 weeks.

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT05663164

Effect of Thiamine on Serum Glucagon And Reactive Oxygen Species (ROS)

Universitas Sumatera Utaran = 301 Oct 2022 to 1 Dec 2022

Sepsis · Thiamine Deficiency

Trial pageClinicalTrials.govUpdated 23 Dec 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.